Close

Cyclo Therapeutics (CYTH) Reports Complete Patient Visit in Phase 1/2 Trial Evaluating Trappsol Cyclo for Treatment of Niemann-Pick Disease Type C

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 4/24/2024

1. TSLA
2. ENPH
3. TXN
4. SPOT
5. V
6. KMB
7. MSFT
8. BA
9. FI
10. STX


Go back to Cyclo Therapeutics (CYTH) Reports Complete Patient Visit in Phase 1/2 Trial Evaluating Trappsol Cyclo for Treatment of Niemann-Pick Disease Type C

Cyclo Therapeutics Announces Last Patient Last Visit in Phase 1/2 Trial Evaluating Trappsol® Cyclo™ for the Treatment of Niemann-Pick Disease Type C

March 4, 2021 9:10 AM EST

Topline results from Phase 1/2 study on track for March 2021

Individual and cumulative data seen to-date show Trappsol® Cyclo to be well tolerated with a favorable safety profile for all dose groups and to have encouraging signals in efficacy

Pivotal Phase 3 study evaluating Trappsol® Cyclo for the treatment of NPC expected to commence enrollment in Q2 2021

GAINESVILLE, Fla.--(BUSINESS... More